To find undiagnosed patients, Zevra's AI model combines a symptom 'suspicion index' with electronic medical records (EMR) and claims data. It flags physicians whose patient populations show patterns consistent with Niemann-Pick Type C, even if misdiagnosed, enabling targeted education to accelerate diagnosis.
Zevra accelerated its transition to a commercial-stage company by acquiring Acer Therapeutics. This strategic move provided a foundational commercial team, specialty pharmacy contracts, and patient advocacy relationships, de-risking their upcoming drug launch by avoiding the distraction of building it all from scratch.
Zevra won't commit to a European commercialization plan (self-launch, partner, or hybrid) until the final regulatory label is approved. The label's specifics will define the drug's value proposition and market size in each country, making it the critical prerequisite for any strategic go-to-market decision.
McFarlane equates the detailed planning of military operations—like establishing a field hospital—with creating a biotech strategic plan. Both require allocating people, time, and money with a clear, mission-driven focus to achieve complex goals, similar to an 'operational order'.
Successful acquisitions are a 'force multiplier' for learning. Instead of seeking an identical culture, Zevra's CEO looks for common missions and an opportunity to learn new competencies—like manufacturing techniques or commercialization strategies—from the acquired company, fostering growth through synergy.
Upon joining Zevra as CEO, Neil McFarlane's first priority was creating focus. He identified filing the New Drug Application (NDA) for their lead rare disease asset as the single greatest value creator and stopped all other distracting activities to channel the organization's resources toward that one goal.
To maintain focus during its pivot to rare diseases, Zevra aggressively culled its portfolio of inherited and acquired assets. This involved deprioritizing programs, returning rights to originators, and divesting entire portfolios to eliminate distractions and monetize non-core intellectual property.
Zevra's CEO argues that while regulatory frameworks have built-in flexibility for rare diseases, the inconsistent application of these rules is the biggest challenge. This uncertainty makes it difficult for companies to know if their development plan and data package will meet the bar for approval upon review.
Unlike typical biotechs that grow from Research to Development to Commercial (R-D-C), Zevra is pursuing a 'C to D to R' model. It focuses first on executing commercially and in late-stage development, using that success to become a partner of choice and eventually earn the right to invest in early-stage research.